Another highlight of Daiichi Sankyo's research history is the invention of levofloxacin in 1985. It was the first quinolone of the third-generation. Levofloxacin is an evolution of ofloxacin, a second-generation quinolone developed by Daiichi Sankyo.
As the presence of Japanese companies on the European market was very limited in the past, levofloxacin has been licensed out for Europe to a partner company. Nevertheless, the product plays a significant role in the therapy of serious and life-threatening bacterial infections.